Effects of a D-Cys[6]/L-Cys[6] Interchange in Nonselective and Selective Vasopressin and Oxytocin Antagonists[†]

Maurice Manning,* Ling Ling Cheng, Wieslaw A. Klis, Lajos Balaspiri,[‡] and Aleksandra Olma[§]

Department of Biochemistry & Molecular Biology, Medical College of Ohio, P.O. Box 10008, Toledo, Ohio 43699-0008

Wilbur H. Sawyer

Department of Pharmacology, College of Physicians and Surgeons of Columbia University, 630 West 168th Street, New York, New York 10032

Nga Ching Wo and W. Y. Chan

Department of Pharmacology, Cornell University Medical College, 1300 York Avenue, New York, New York 10021

We report the solid-phase synthesis of the D-Cys[6] analogues of arginine-vasopressin (AVP), peptide **1**, of the selective AVP vasopressor (V_{1a} receptor) antagonist [1-(β-mercapto-β,β-pentamethylenepropionic acid),2-O-methyltyrosine]arginine-vasopressin ($d(CH_2)_5[Tyr(Me)^2]$-AVP, (A)), peptide **2**, of the three nonselective antidiuretic/vasopressor (V_2/V_{1a} receptor) AVP antagonists $d(CH_2)_5[Tyr(Et)^2]VAVP$ (B), $d(CH_2)_5[D-Tyr(Et)^2]VAVP$ (C), and $d(CH_2)_5[D-Phe^2]VAVP$ (D) (where V = Val[4]), peptides **3–5**, of the nonselective oxytocin (OT) antagonists $d(CH_2)_5$-$[Tyr(Me)^2]OVT$ (E) and $d(CH_2)_5[Tyr(Me)^2,Thr^4,Tyr-NH_2^9]OVT$ (F) (where OVT = ornithine-vasotocin), peptides **6** and **7**, and of the selective OT antagonists desGly-$NH_2,d(CH_2)_5[Tyr(Me)^2,Thr^4]OVT$ (G) and $d(CH_2)_5[D-Trp^2,Thr^4]OVT$ (H), peptides **8** and **9**. We also present the repeat syntheses of the previously reported $d(CH_2)_5[D-Trp^2]AVT$ (peptide **10**) and its D-Cys[6] analogue (peptide **11**) (where AVT = arginine-vasotocin). Peptides **1–11** were assayed for agonist and antagonistic activities in *in vivo* V_{1a}, V_2, and oxytocic assays and in *in vitro* oxytocic assays without and with 0.5 mM Mg^{2+}. With V_2 and V_{1a} agonistic potencies of 0.82 and 0.41 units/mg, [D-Cys[6]]AVP has retained less than 0.3% of the V_2 and V_{1a} potencies of AVP. It exhibits no oxytocic activity and is an *in vitro* OT antagonist. $pA_2 = 6.67$ (no Mg^{2+}); $pA_2 = 5.24$ (0.5 mM Mg^{2+}). By contrast, with one or two exceptions, a D-Cys[6]/L-Cys[6] interchange in antagonists **2–9**, although resulting in reductions of antagonistic potencies in all assays for virtually all peptides **2–9** relative to A–H, has been well tolerated. For peptides **2–5**, the anti-V_2 and anti-V_{1a} pA_2 values range from ~5.54 to 7.33 and from 7.19 to 8.06, respectively; the range of *in vitro* anti-OT pA_2 values (no Mg^{2+}) is 7.35–7.87; with 0.5 mM Mg^{2+}, the range is 7.24–8.21. Peptides **2** and **4** have *in vivo* anti-OT pA_2s = 6.60 and 7.16, respectively. For peptides **6–9**, the range of *in vitro* anti-OT pA_2 values (no Mg^{2+}) is 7.65–7.96; with 0.5 mM Mg^{2+}, the range is 7.41–7.65, and the *in vivo* anti-OT pA_2 values range from 6.85 to 7.33. With an *in vivo* anti-OT $pA_2 = 7.33$, peptide **6** is equipotent with its parent E. The *in vivo* anti-OT potencies of peptides **7–9** are significantly reduced relative to those of F–H. The *in vitro* anti-OT (0.5 mM Mg^{2+}) pA_2 values of **10** and **11** are 7.54 and 7.50, both significantly lower than those previously reported. Peptides **10** and **11** exhibit substantial V_{1a} antagonism. Their anti-V_{1a} pA_2 values are 7.56 and 7.53, respectively. The findings on peptides **2–9** show that a D-Cys[6]/L-Cys[6] interchange in cyclic AVP and OT antagonists may be of limited value in enhancing antagonistic potency or selectivity. However, when combined with other appropriate molecular modifications, this interchange may be of merit for the design of orally active AVP and OT antagonists.

Antagonists of arginine-vasopressin (AVP) and oxytocin (OT) are widely used as powerful pharmacological

tools in studies on the physiological, pathophysiological, and behavioral roles of these two peptides.[1] As tritiated and radioiodinated derivatives, AVP and OT agonists and antagonists are proving to be very useful radioligands in receptor localization and characterization studies.[2,3] AVP and OT agonists and antagonists have been utilized to help characterize the binding affinities and specifities of recently cloned AVP V_{1a}, V_{1b}, and V_2 receptors[4–9] from humans, rat, and pig and of the human oxytocin uterine receptor.[10a] They have continued to be valuable tools in the discovery of new receptor subtypes as shown by the recent demonstration of two receptor subtypes in the pregnant rat uterus.[10b,c] V_{1a} receptors present in the vasculature mediate the pressor action of AVP, and they are also present in brain, liver, and other tissues mediating the various biological

actions of AVP.[1,11-13] V_{1b} receptors, present in the anterior pituitary, mediate the ACTH-releasing effects of AVP.[13] V_2 receptors, present in the kidney, mediate the antidiuretic action of AVP.[13-15] OT receptors, present in the uterus, mediate the uterine-contracting (oxytocic) effect of oxytocin.[16] Besides their value as pharmacological tools and radioligands, AVP and OT antagonists are of potential clinical value.[1] AVP V_2 antagonists have potential therapeutic value for the treatment of hyponatremia caused by the syndrome of inappropriate secretion of the antidiuretic hormone (SIADH).[17] Antagonists of the vascular responses (V_{1a} receptor) to AVP may have clinical potential for the treatment of those patients with hypertension or congestive heart failure with concomitant elevated plasma AVP levels.[1,18] Antagonists of OT are of potential therapeutic value for the prevention of premature labor.[1] In this regard, an OT antagonist [1-deamino,D-Tyr(Et)²,Thr⁴]ornithine-vasotocin (tradename: ATOSIBAN) is currently undergoing clinical trial for this purpose.[19] Recently discovered orally active nonpeptide antagonists of OT and AVP[20,23] offer potentially attractive new therapeutic agents in this field. To date, no clinical trials with nonpeptide AVP or OT antagonists have been reported.

Over the years, we and others have carried out extensive investigations aimed at improving the potency, receptor selectivity, and oral bioavailability of AVP V_{1a}, V_2, and OT uterine antagonists. For reviews, see refs 1 and 24-28. The present study on the effectiveness of a D-Cys⁶/L-Cys⁶ interchange in AVP and OT antagonist design is a continuation of a preliminary investigation carried out some years ago.[29] Our renewed interest in a D-Cys⁶/L-Cys⁶ interchange was sparked by a recent report[30] which is somewhat at variance with our earlier findings.[29] We had found that a D-Cys⁶/L-Cys⁶ interchange in the three nonselective AVP V_2/V_{1a} antagonists d(CH₂)₅[Tyr(Et)²]VAVP,[32a] d(CH₂)₅[D-Tyr(Et)²]VAVP,[32b] and d(CH₂)₅[D-Phe²]VAVP[33] (peptides B–D; Table 2) to give peptides 3–5 (Table 2) led to a drastic loss of V_2 antagonism for peptide 3 and fairly substantial losses of V_2 antagonism for peptides 4 and 5.[29] Although V_{1a} antagonism was fully retained in peptide 4, substantial losses were sustained in peptides 3 and 5. Furthermore, in unpublished findings, we found that *in vitro* oxytocic antagonism (in the absence of Mg^{2+}) was reduced 2–5-fold in peptides 3–5. Oxytocic antagonism in the presence of 0.5 mM Mg^{2+} was also reduced to a lesser extent in all three peptides 3–5. *In vivo* OT antagonism of peptide 4 was reduced by ~50% relative to that of its parent peptide C. These findings showed that while a D-Cys⁶/L-Cys⁶ interchange in AVP V_2/V_{1a} antagonists exerts variable and inconsistent effects on antagonistic potencies, in no instance was antagonistic potency enhanced.

We were thus most intrigued by a recent report[30] that a D-Cys⁶ substitution in the OT antagonist d(CH₂)₅[D-Trp²]AVT[34] resulted in an apparent 3-fold enhancement in *in vitro* antioxytocic potency in the presence of 0.5 mM Mg^{2+} and which also suggested that a D-Cys⁶/L-Cys⁶ interchange might be a promising new lead in OT antagonist design.[30] These findings and conclusions were clearly different from our earlier published[29] and unpublished findings and with those more recently reported by others[31] on the effects of a D-Cys⁶/L-Cys⁶ interchange in a series of AVP V_2/V_{1a} antagonists.[31]

However, since we and this more recent study[31] had utilized AVP-derived V_2/V_{1a} antagonists, which have a vasopressin-like ring with Phe at position 3, and this very recent study[30] had utilized an AVT-derived OT antagonist, which has an OT-like ring with Ile at position 3, there was the possibility that the contrasting effects on antagonistic potencies of a D-Cys⁶/L-Cys⁶ interchange observed in these studies[29-31] was due to the different ring structures of the parent AVP and OT antagonists. We thus decided to return to and expand our earlier investigation[29] to include an examination of the effects of D-Cys⁶/L-Cys⁶ interchange in four of our most potent and selective OT antagonists, d(CH₂)₅[Tyr-(Me)²]OVT,[35] d(CH₂)₅[Tyr(Me)²,Thr⁴,Tyr-NH₂⁹]OVT,[35] desGly-NH₂,d(CH₂)₅[Tyr(Me)²,Thr⁴]OVT,[35] and desGly-NH₂,d(CH₂)₅[D-Trp²,Thr⁴]OVT,[36] peptides E−H (Table 3), to give peptides 6−9 (Table 3). We also included an investigation of the effects of a D-Cys⁶/L-Cys⁶ interchange in the AVP V_{1a} antagonist d(CH₂)₅[Tyr(Me)²]-AVP[37] (peptide A; Table 2) to give peptide 2 (Table 2). When our preliminary findings on peptides 2 and 6−9[38] appeared to concur with our earlier findings[29] and those of Albrightson-Winslow and colleagues,[31] while being inconsistent with those of Flouret and colleagues for d(CH₂)₅[D-Trp²,D-Cys⁶]AVT,[30] we decided to repeat the syntheses and pharmacological evaluation of this peptide[30] and its L-Cys⁶ parent d(CH₂)₅[D-Trp²]AVT.[34] Our findings on our synthetic preparations of those two peptides (10 and 11) are also presented in this report. Finally, to compare and contrast the effects of a D-Cys⁶/L-Cys⁶ interchange in AVP and OT agonists and antagonists, we report here also the synthesis and some pharmacological properties of [D-Cys⁶]AVP (peptide 1; Table 1). It will be recalled that [D-Cys⁶]OT (Table 1) was shown to be virtually devoid of agonistic activities.[39]

We thus report the synthesis and some pharmacological properties of the following 11 peptides designed according to the above rationale: 1, [D-Cys⁶]AVP; 2, d(CH₂)₅[Tyr(Me)²,D-Cys⁶]AVP; 3, d(CH₂)₅[Tyr(Et)²,D-Cys⁶]VAVP; 4, d(CH₂)₅[D-Tyr(Et)²,D-Cys⁶]VAVP; 5, d(CH₂)₅[D-Phe²,D-Cys⁶]VAVP; 6, d(CH₂)₅[Tyr(Me)²,D-Cys⁶]OVT; 7, d(CH₂)₅[Tyr(Me)²,Thr⁴,D-Cys⁶,Tyr-NH₂⁹]-OVT; 8, desGly-NH₂,d(CH₂)₅[Tyr(Me)²,Thr⁴,D-Cys⁶]OVT; 9, desGly-NH₂,d(CH₂)₅[D-Trp²,Thr⁴,D-Cys⁶]OVT; 10, d(CH₂)₅[D-Trp²]AVT; and 11, d(CH₂)₅[D-Trp²,D-Cys⁶]-AVT. Peptide 1 is the D-Cys⁶ analogue of the V_2/V_{1a}/OT agonist AVP. Peptides 2−5 are D-Cys⁶ analogues of the AVP V_{1a}/OT antagonist A and the AVP V_2/V_{1a}/OT antagonists B−D. Peptides 6−9 are D-Cys⁶ analogues of nonselective (E, F) and selective (G, H) OT/V_{1a} antagonists. Peptides 10 and 11 are repeat syntheses of peptides originally synthesized in the Flouret laboratory.[30,34]

Analogues 2−5, which have an AVP-like ring, have the following general structure:

no.	X²	Y⁴
2	Tyr(Me)	Gln
3	Tyr(Et)	Val
4	D-Tyr(Et)	Val
5	D-Phe	Val

Analogues 6−9, which have an OT-like ring, have the following general structure:

$$ \underset{1}{CH_2}\text{-}\underset{2}{CO}\text{-}\underset{3}{X}\text{-}\underset{4}{Ile}\text{-}\underset{5}{Y}\text{-}\underset{6}{Asn}\text{-}\underset{}{D\text{-}Cy}\text{-}\underset{7}{Pro}\text{-}\underset{8}{Orn}\text{-}\underset{9}{Z} $$

no.	X^2	Y^4	Z^9
6	Tyr(Me)	Gln	Gly-NH$_2$
7	Tyr(Me)	Thr	Tyr-NH$_2$
8	Tyr(Me)	Thr	
9	D-Trp	Thr	

Analogues **10** and **11**, which have an OT-like ring, have the following general structure:

$$ \underset{1}{CH_2}\text{-}\underset{2}{CO}\text{-}\underset{3}{D\text{-}Trp}\text{-}\underset{4}{Ile}\text{-}\underset{5}{Gln}\text{-}\underset{6}{Asn}\text{-}\underset{7}{X}\text{-}\underset{8}{Pro}\text{-}\underset{}{Arg}\text{-}\underset{9}{Gly}\text{-}NH_2 $$

no.	X^6
10	L-Cys
11	D-Cys

Peptide Synthesis

Starting from Boc-Gly-resin, Boc-Orn(Tos)-resin, or Boc-Tyr(Bzl)-resin, we synthesized the protected precursors **I–XI** of the free peptides **1–11** by solid-phase peptide synthesis according to previously published procedures.[31–33,40–42] HCl (1 M)/AcOH was used in all deprotection steps excluding those involving Boc-Gln.[42a] A 10% solution of TEA in DCM was used for neutralizations. Couplings were carried out by DCC preformed symmetrical anhydrides for peptides **I–V** and DCC/HOBt[43] for peptides **VI–XI**, except for Boc-Asn and Boc-Gln, which were incorporated as their *p*-nitrophenyl esters.[44] Also, in the case of peptides **II–V**, β-(benzylthio)-β,β-pentamethylenepropionic acid[45] was added as its *p*-nitrophenyl ester. Peptides were cleaved from the resin by ammonolysis as protected peptide amides (peptides **I–VII, X**, and **XI**)[42,46] or by HBr/TFA to give the protected peptide carboxylic acids (peptides **VIII** and **IX**).[40b,41,47,48] All protected peptides were purified by a series of precipitations. Peptides were deprotected by sodium in liquid ammonia[49] as previously described.[50–52] The disulfides were formed by oxidative cyclization with potassium ferricyanide using the normal procedure (peptides **1–5, 10**, and **11**)[52] or a reverse procedure (peptides **6–9**).[53] The free peptides were desalted by gel filtration on a Sephadex G-15 column eluted with 50% AcOH and further purified on a G-15 column eluted with 0.2 M AcOH (peptides **1–5**) or on a LH-20 Sephadex column eluted with 2.0 M AcOH (peptides **6–11**) as previously described.[54] All free peptides were examined by TLC and HPLC for purity and by amino acid analysis and mass spectroscopy for chemical composition. Additionally, all free D-Cys^6 peptides were examined by HPLC for diastereoisomeric peptide contamination by coinjection with the corresponding L-Cys^6 peptide.

Bioassays

Peptides were assayed for agonistic and antagonistic activities in *in vitro* and *in vivo* rat oxytocic assays, rat vasopressor assays, and rat antidiuretic assays. For agonists, the 4-point assay design[55] was used, and for antagonists, the Schild's pA_2 method[56] was employed. The pA_2 is the negative logarithm of the molar concentration of the antagonist that will reduce the response to $2x$ units of the agonist to equal the response to x unit of the agonist in the absence of antagonist. In practice, this dose is estimated by finding doses above and below

the pA_2 dose and interpolating on a logarithmic scale. In the rat *in vivo* assays, the pA_2 dose (effective dose, ED) is divided by an arbitrarily assumed volume of distribution of 67 mL/kg to estimate the molar concentration of the pA_2 dose. Thus, *in vivo* pA_2 values are estimates. USP posterior pituitary reference standards or synthetic oxytocin and arginine-vasopressin which had been standardized in oxytocic and vasopressor units against the USP posterior pituitary reference standard were used as working standards in all bioassays. *In vitro* oxytocic assays were performed on isolated uteri from diethylstilbestrol-primed rats in a Mg^{2+}-free van Dyke–Hasting solution.[57] *In vivo* anti-OT potencies were determined in urethane-anesthetized diethylstilbestrol-primed rats as previously described.[58] Vasopressor assays were performed on urethane-anesthetized and phenoxybenzamine-treated rats as described by Dekanski.[59] Antidiuretic assays were on water-loaded rats under ethanol anesthesia as described by Sawyer.[60] For all *in vivo* assays, doses of the peptide were injected intravenously. When standard errors are presented in the tables, the means reflect results from at least four independent assay groups.

Results and Discussion

Data on the effects of a D-Cys^6/L-Cys^6 interchange in AVP and OT[39] are given in Table 1. Data on the effects of a D-Cys^6/L-Cys^6 interchange in the AVP V$_{1a}$ antagonist (A) and the three V$_2$/V$_{1a}$ antagonists (B–D) are given in Table 2 (peptides **2–5**). The effects of a D-Cys^6/L-Cys^6 interchange in the two nonselective OT antagonists (E, F) and the two selective OT antagonists (G, H) are given in Table 3 (peptides **6–9**). Data from our resyntheses of d(CH$_2$)$_5$[D-Trp^2]AVT^{34} and its D-Cys^6 analogue[30] (peptides **10** and **11**) together with the original data reported by Flouret and colleagues[34,30] are also presented in Table 3.

Comparison of Effects of D-Cys^6/L-Cys^6 Interchange in AVP and OT (Table 1). The replacement of L-Cys^6 by D-Cys^6 in oxytocin led to drastic losses of *in vitro* oxytocic activity and *in vivo* antidiuretic and vasopressor activities.[39] We now report similar losses of agonistic activities for [D-Cys^6]AVP (Table 1). Remarkably, [D-Cys^6]AVP is an antagonist in the *in vitro* oxytocic assays. Thus, these findings prove conclusively that a D-Cys^6/L-Cys^6 interchange in both oxytocin and vasopressin is not compatible with retention of agonistic activities. However, this does not rule out the possibility that a D-Cys^6/L-Cys^6 interchange might be better tolerated in other agonistic analogues of AVP and possibly also of OT.

Effects of a D-Cys^6/L-Cys^6 Interchange in AVP V$_{1a}$ and V$_2$/V$_{1a}$ Antagonists (Table 2). In a preliminary report,[29] we had previously shown that a D-Cys^6/L-Cys^6 interchange in the three nonselective V$_2$/V$_{1a}$ AVP antagonists B–D (Table 2) to give peptides **3–5** (Table 2) resulted in significant, and in one case (peptide **3**) drastic, losses of both V$_2$ and V$_{1a}$ antagonism. Thus, it is not surprising that the D-Cys^6 analogue of the selective V$_{1a}$ antagonist A (Table 2), i.e., peptide **2** reported here, also exhibits a significant loss of V$_{1a}$ antagonism relative to A. With an anti-V$_{1a}$ pA_2 = 7.87, peptide **2** is only about $^1/_6$ as potent as its parent A. Interestingly, a D-Cys^6/L-Cys^6 interchange in d(CH$_2$)$_5$-[Tyr(Me)^2]AVP abolished V$_2$ agonism. The D-Cys^6 peptide **2** is a weak V$_2$ antagonist. We now report that all four

Table 1. Some Pharmacological Properties of D-Cys^6 Analogues of Oxytocin (OT) and Arginine-vasopressin (AVP)

$$\overset{1}{\text{Cys}}-\overset{2}{\text{Tyr}}-\overset{3^*}{\text{Phe}}-\overset{4}{\text{Gln}}-\overset{5}{\text{Asn}}-\overset{6}{\text{Cys}}-\overset{7}{\text{Pro}}-\overset{8^*}{\text{Arg}}-\overset{9}{\text{Gly}}-\text{NH}_2$$

no.	peptide	oxytocic activity (U/mg)		antidiuretic act. (U/mg) (V$_2$ receptor)	vasopressor act. (U/mg) (V$_{1a}$ receptor)
		no Mg^{2+}	0.5 mM Mg^{2+}		
	oxytocin (OT)^a	520 ± 12	486 ± 15	4 ± 0.8	4.3 ± 0.12
	[D-Cys^6]OT^b	0.62		<0.002	<0.002 (antagonist)
	Arg-vasopressin (AVP)^a	13.9 ± 0.5	25.5 ± 0	323 ± 16	369 ± 6
1	[D-Cys^6]AVP^c	antagonist (pA$_2$ = 6.67 ± 0.06)	mixed^d (pA$_2$ ~ 5.24)	0.82 ± 0.15	0.41 ± 0.03

* In oxytocin positions 3 and 8 are occupied by Ile and Leu, respectively. ^{a} Data from ref 16b. ^{b} Data from ref 39. ^{c} This publication. ^{d} Exhibits some agonist activity as well as antagonist activity.

Table 2. Pharmacological Properties of D-Cys^6 Analogues of V$_{1a}$ and V$_2$/V$_{1a}$ Antagonists of Arginine-vasopressin

no.	peptide	antiantidiuretic (anti-V$_2$)		antivasopressor (anti-V$_{1a}$)		antioxytocic *in vitro* pA$_2$^{a}		*in vivo*	
		ED^b	pA$_2$^{c}	ED^b	pA$_2$^{c}	no Mg^{2+}	0.5 mM Mg^{2+}	ED^b	pA$_2$^{c}
A	d(CH$_2$)$_5$[Tyr(Me)^2]AVP^f	agonist (0.31 ± 0.07 U/mg)		0.16 ± 0.01^d	8.62 ± 0.03	8.13 ± 0.12	7.24 ± 0.07	17 ± 3	6.62 ± 0.07
2	D-Cys^6 analogue of A^e	~194	~5.54	0.96 ± 0.24	7.87 ± 0.09	7.87 ± 0.06	7.60 ± 0.05	17 ± 1	6.60 ± 0.02
B	d(CH$_2$)$_5$[Tyr(Et)^2]VAVP^{e,g}	1.9 ± 0.2^g	7.57 ± 0.6^g	0.49 ± 0.11^g	8.16 ± 0.09^g	7.88 ± 0.10^e	7.53 ± 0.07^e	13 ± 2^e	6.74 ± 0.0^e
3	D-Cys^6 analogue of B^{e,j}	~72^j	~6^j	4.4 ± 0.5^j	7.19 ± 0.05^j	7.59 ± 0.09^e	7.24 ± 0.10^e		
C	d(CH$_2$)$_5$[D-Tyr(Et)^2]VAVP^{h,k}	1.1 ± 0.2	7.81 ± 0.7	0.45 ± 0.11	8.22 ± 0.12	8.32 ± 0.10^k	8.38 ± 0.08^k	2.6 ± 0.6^k	7.47 ± 0.09^k
4	D-Cys^6 analogue of C^{e,j}	3.3 ± 0.7^j	7.33 ± 0.07^j	0.60 ± 0.05^j	8.06 ± 0.05^j	7.43 ± 0.07^e	8.21 ± 0.03^e	4.8 ± 0.8^e	7.16 ± 0.09^e
D	d(CH$_2$)$_5$[D-Phe^2]VAVP^i	0.67 ± 0.13	8.07 ± 0.09	0.58 ± 0.04	8.06 ± 0.03	7.74 ± 0.06	8.29 ± 0.05	8.9 ± 1.9	6.92 ± 0.10
5	D-Cys^6 analogue of D^{e,j}	3.9 ± 0.5^j	7.25 ± 0.06^j	1.9 ± 0.4^j	7.56 ± 0.07^j	7.35 ± 0.05^e	7.97 ± 0.06^e		

^{a} *In vitro* pA$_2$ values represent the negative logarithm to the base 10 of the average molar concentration (M) of antagonist which reduces the response to 2x units of agonist to the response with x unit of agonist. ^{b} The effective dose (ED) is defined as the dose (in nmols/kg) of antagonist that reduces the response to 2x units of agonist to the response with x unit of agonist administered in the absence of antagonist. ^{c} Estimated *in vivo* pA$_2$ values represent the negative logarithms of the "effective dose" in mol/kg divided by the estimated volume of distribution (67 mL/kg). ^{d} Means ± SE. ^{e} This publication. ^{f} Data from ref 37. ^{g} Data from ref 32a. ^{h} Data from ref 32b. ^{i} Data from ref 33. ^{j} Data from ref 29. ^{k} Data from ref 35.

D-Cys^6 analogues, **2–5** (Table 2), exhibit reductions in antioxytocic potencies *in vitro* (0 Mg^{2+}). Three of the four peptides, i.e., **3–5** (Table 2), also exhibit reductions in antioxytocic potencies *in vitro* (0.5 mM Mg^{2+}). Only one analogue (**2**) exhibited an enhancement of anti-OT potency *in vitro* (0.5 mM Mg^{2+}). *In vivo* anti-OT potency was retained in one case (peptide **2**) and reduced in the other (peptide **4**) of the two D-Cys^6 analogues tested on this assay to date. Thus, in AVP V$_2$/V$_{1a}$ antagonists, while a D-Cys^6/L-Cys^6 interchange appears to preserve the ability to bind to V$_2$/V$_{1a}$ and OT receptors and to thereby retain antagonistic potencies, it has not enhanced antagonistic potencies. Furthermore, the results of a D-Cys^6/L-Cys^6 interchange appear to be very structure dependent with regard to losses of V$_2$ antagonism. Thus, the D-Cys^6 analogues **3–5** retain respectively only ~3%, ~33%, and 17% of the V$_2$ antagonism of their respective parent peptides B–D (Table 2). Whether a D-Cys^6 substitution in an AVP V$_2$/V$_{1a}$ antagonist will result in a drastic or a fairly substantial loss of V$_2$ antagonistic potency cannot be predicted. As noted above, the effects of a D-Cys^6 substitution on the V$_{1a}$ antagonism of V$_2$/V$_{1a}$ antagonists appear not to be as drastic as the losses of V$_2$ antagonism. Although losses of V$_{1a}$ antagonism were sustained for peptides **3** and **5**, these were much less in each case than the loss in each case of V$_2$ antagonism. Peptide **4** is virtually equipotent with its parent peptide C as a V$_{1a}$ antagonist.

We can conclude from the data on peptides **2–5**, all of which contain a vasopressin ring, that a D-Cys^6/L-Cys^6 interchange in a V$_{1a}$ antagonist and in three V$_2$/V$_{1a}$ antagonists, although leading to losses of V$_2$, V$_{1a}$, and OT antagonism, does not abolish the ability to bind to V$_2$, V$_{1a}$, or OT receptors. These findings suggest the possibility that D-Cys^6 substitutions could, in combination with other appropriate structural modifications, be of value in the design of orally active AVP V$_2$/V$_{1a}$ and OT antagonists. The findings on the effects of a D-Cys^6/L-Cys^6 interchange in cyclic AVP V$_2$/V$_{1a}$ antagonists are remarkably similar to those we have recently reported for a D-Abu^6/L-Abu^6 interchange in a series of linear AVP V$_2$/V$_{1a}$ antagonists.[61]

Effects of a D-Cys^6/L-Cys^6 Interchange in Oxytocin Antagonists, Peptides 6–9 and 11 (Table 3). In peptides **6**, **8**, and **9**, a D-Cys^6/L-Cys^6 interchange reduced anti-OT potencies *in vitro*, in the absence of Mg^{2+}. The anti-OT potency of peptide **7** remained unchanged in this assay. In the presence of Mg^{2+}, the anti-OT potencies of peptides **6**, **7**, and **8** were diminished but that of peptide **9** was unchanged. These findings are in striking contrast to those reported by others[30] for the D-Cys^6/L-Cys^6 analogue pair **10** and **11** (Table 3). In our assays, the newly synthesized peptides **10** and **11** exhibit reduced anti-OT potency (*in vitro*, 0.5 mM Mg^{2+}) compared to those reported originally.[30,34] Furthermore, it may be noted that although *in vitro* OT antagonism is fully retained in the D-Cys^6 analogue (**11**), we have not observed the 3-fold enhancement in OT antagonism observed in the original report on the peptide.[30] We have no explanations for these discrepancies except to point out that assays were carried out on different preparations of these two peptides in different laboratories. Our findings on the effects of a D-Cys^6/L-Cys^6 interchange in all the OT antagonists studied to date appear to be consistent with those we had previously observed for this interchange in AVP V$_2$/V$_{1a}$ antagonists.[29] This interchange appears not to enhance antagonistic potency as suggested by the Flouret et al. report.[30] On the contrary, with only one or two exceptions, it results in losses of antagonistic potencies. When assayed *in vivo*, the three D-Cys^6 OT antagonists, **7–9**, exhibited significant losses of anti-

Table 3. Some Pharmacological Properties of D-Cys^6 Analogues of Selective and Nonselective Oxytocin Antagonists

		antioxytocic in vitro pA_2[a]		antioxytocic in vivo		antivasopressor		antidiuretic activity	
no.	peptide	no Mg^{2+}	0.5 mM Mg^{2+}	ED[b]	pA_2[c]	ED[b]	pA_2[c]	U/mg	ED[j] ratio
E	$d(CH_2)_5$[Tyr(Me)^2]OVT[e]	8.52 ± 0.10[d]	7.88 ± 0.10	4.2 ± 1.6	7.37 ± 0.17	0.80 ± 0.16	7.96 ± 0.10	~0.01	0.2
6	D-Cys^6 analogue of E[f]	7.65 ± 0.07	7.44 ± 0.05	3.11 ± 0.51	7.33 ± 0.07	3.73 ± 0.15	7.25 ± 0.02	antagonist (pA_2 ~ 5.9)	1.0
F	$d(CH_2)_5$[Tyr(Me)^2,Thr^4, Tyr-NH$_2$^{9}]OVT[e]	7.63 ± 0.07	8.28 ± 0.10	1.0 ± 0.1	7.83 ± 0.04	6.6 ± 0.9	7.02 ± 0.07	~0.015	6.6
7	D-Cys^6 analogue of F[f]	7.96 ± 0.05	7.41 ± 0.08	5.63 ± 0.93	7.08 ± 0.08	10 ± 2	6.83 ± 0.09	antagonist (pA_2 ~ 5.5)	1.8
G	desGly-NH$_2$,$d(CH_2)_5$[Tyr(Me)^2,Thr^4]OVT[e]	7.89 ± 0.04	8.24 ± 0.09	1.3 ± 0.2	7.69 ± 0.07	23 ± 4	6.48 ± 0.08	antagonist (pA_2 ~ 5.5)	17.7
8	D-Cys^6 analogue of G[f]	7.73 ± 0.07	7.60 ± 0.06	9.24 ± 1.85	6.86 ± 0.10	17.3 ± 2.0	6.56 ± 0.05	antagonist (pA_2 ~ 5.4)	
H	desGly-NH$_2$,$d(CH_2)_5$[D-Trp^2,Thr^4]OVT[g]	8.02 ± 0.03	7.64 ± 0.05[f]	3.08 ± 0.59	7.34 ± 0.09	248 ± 23	5.43 ± 0.04	~0.01	80
9	D-Cys^6 analogue of H[f]	7.83 ± 0.04	7.65 ± 0.08	9.42 ± 1.82	6.85 ± 0.08	20 ± 2	6.52 ± 0.03	pA_2 ~ 5.5	2.1
10	$d(CH_2)_5$[D-Trp^2]AVT[f,h]		7.77 ± 0.03[h]					antagonist (pA_2 < 5.9)[h]	
			7.54 ± 0.07[f]			2.0 ± 0.3[f]	7.56 ± 0.06[f]		
11	D-Cys^6 analogue of 10[f,i]		8.29 ± 0.23[i]					antagonist (pA_2 < 6.3)	
			7.50 ± 0.06[f]			2.0 ± 0.3[f]	7.53 ± 0.05[f]	pA_2 < 5.6	

a,b,c,d See corresponding footnotes Table 2. [e] Data from reference 35. [f] This publication. [g] Data from reference 36. [h] Data from reference 34. [i] Data from reference 30. [j] ED ratio = antivasopressor ED/antioxytocic ED.

OT potencies with respect to their parent peptides F—H. By contrast, the D-Cys^6 OT antagonist **6**, although losing *in vitro* anti-OT potency, retained full *in vivo* anti-OT potency relative to its parent peptide E. All four D-Cys^6 OT antagonists, **6—9**, exhibited weak anti-V$_2$ activity. Remarkably, a D-Cys^6/L-Cys^6 interchange appears to have had inconsistent effects on the anti-V$_{1a}$ potencies of the four new D-Cys^6/L-Cys^6 pairs and in the resynthesized pair (peptides **10** and **11**). One of the peptides (peptide **6**) exhibits a substantial reduction in anti-V$_{1a}$ potency with respect to its parent peptide E. Another peptide (**9**) exhibits a significant gain in anti-V$_{1a}$ potency with respect to its parent peptide H. The anti-V$_{1a}$ potencies of the remaining three peptides, **7**, **8**, and **11**, are not significantly different than those of their respective parents F, G, and **10**. Thus, none of the D-Cys^6 OT antagonists (**6—8**) exhibit significant gains in anti-OT/anti-V$_{1a}$ selectivity *in vivo*. While a D-Cys^6/L-Cys^6 substitution in these OT antagonists has not resulted in enhanced OT antagonism or selectivity, the retention of full *in vivo* OT antagonism by peptide **6**, and the partial but significant retention of *in vivo* OT antagonism by peptides **7—9**, lends support to the view that D-Cys^6 substitutions may be of value in OT antagonist design.[30] As noted above for AVP V$_2$/V$_{1a}$ and V$_{1a}$ antagonists, D-Cys^6 substitutions, in combination with other structural modifications, may have potential in the design of orally active OT antagonists.

Conclusions

Our findings on the effects of a D-Cys^6/L-Cys^6 interchange in AVP are consistent with those previously reported for this interchange in OT.[39] Thus, a D-Cys^6/L-Cys^6 interchange in AVP also leads to drastic losses of agonistic activities. By contrast, as we and others have previously noted, a D-Cys^6/L-Cys^6 interchange is much better tolerated in AVP and OT antagonists.[29,30] Although we could not confirm the dramatic increase in *in vitro* (0.5 mM Mg^{2+}) OT antagonism previously reported for $d(CH_2)_5$[D-Trp^2,D-Cys^6]AVT,[30] our findings show that the effects of a D-Cys^6/L-Cys^6 interchange in OT antagonists reported here are consistent with those

we have reported earlier on the effects of this interchange in AVP V$_2$/V$_{1a}$ antagonists.[29] With only one or two exceptions, a D-Cys^6/L-Cys^6 interchange does not enhance antagonistic potencies. In only a few instances is full antagonism retained. In the majority of cases, a D-Cys^6 substitution brought about substantial losses of antagonistic potencies in one or more assays. Nevertheless, all the D-Cys^6 antagonists retain the ability to bind to their receptors. Although a D-Cys^6/L-Cys^6 interchange appears to have limited value for increasing either the potency or the selectivity of the AVP or OT antagonists reported in this paper, nonetheless, the retention of full *in vivo* antagonism by the D-Cys^6 peptide **6** is encouraging. Thus, the potential of a D-Cys^6/L-Cys^6 interchange for the design of other AVP V$_{1a}$ and V$_2$ antagonists and OT antagonists and also for orally active peptides merits further exploration.

Experimental Section

Amino acid derivatives were purchased from Bachem Inc. or Chemalog Inc. Boc-Tyr(Me),[62] Boc-Tyr(Et),[62] Boc-D-Tyr(Et),[62] β-(benzylthio)-β,β-pentamethylenepropionic acid,[45] and p-nitrophenyl β-(benzylthio)-β,β-pentamethylenepropionate[45] were synthesized by previously published procedures. Thin layer chromatography (TLC) was run on precoated silica gel plates (60F-254, E. Merck) with the following systems: (a) 1-butanol:AcOH:H$_2$O (4:1:5, upper phase), (b) 1-butanol:AcOH:H$_2$O (4:1:1), (c) 1-butanol:AcOH:H$_2$O:pyridine (15:3:3:10), and (d) chloroform:methanol (7:3). Loads of 10—15 μg were applied, and chromatograms were developed at minimal length of 10 cm. The chlorine gas procedure for the KI-starch reagent and I$_2$ were used for detection.[41] Optical rotations were measured with a Rudolph Autopol III polarimeter. Amino acid analyses were done by Commonwealth Biotechnologies Inc. or the University of Louisville Core Facility. Molar ratios were referred to Phe or Gly = 1. Tyr(Et) and Tyr(Me) were detected as Tyr without substantial losses in 28 h hydrolyses. All peptides gave the expected amino acid ratios ±5%. Analytical high-performance liquid chromatography (HPLC) was performed on a Waters 810 instrument equipped with a Rainin Microsorb C$_{18}$ column using a linear gradient (1%/min) of 10—70% acetonitrile containing 0.05% of TFA in 0.05% aqueous trifluoroacetic acid at a flow rate of 1 mL/min with UV detection at 210 nm. All peptides were at least 95% pure. Furthermore, coinjection of each D-Cys^6 peptide with its L-Cys^6 diastereoisomer, with the exception of the D-Cys^6/L-Cys^6 AVP

Table 4. Physicochemical Properties of Protected Peptides **I–XI**

no.[a]	structure	yield[b] (%)	mp (°C)	$[\alpha]^{25}_D$ (deg) (c 1, DMF)	TLC, R_f[c] a	b	c	d
I	Cbz-Cys(Bzl)-Tyr(Bzl)-Phe-Gln-Asn-D-Cys(Bzl)-Pro-Arg(Tos)-Gly-NH₂	30	167–9	−25.6	0.71	0.63	0.86	0.87
II	d(CH₂)₅(Bzl)-Tyr(Me)-Phe-Gln-Asn-D-Cys(Bzl)-Pro-Arg(Tos)-Gly-NH₂	64	148–50	−22.4	0.68	0.61	0.86	0.84
III	d(CH₂)₅(Bzl)-Tyr(Et)-Phe-Val-Asn-D-Cys(Bzl)-Pro-Arg(Tos)-Gly-NH₂	58.4	158–60	−28.9	0.75	0.77	0.82	0.90
IV	d(CH₂)₅(Bzl)-D-Tyr(Et)Phe-Val-Asn-D-Cys(Bzl)-Pro-Arg(Tos)-Gly-NH₂	29.0	167–9	−7.6		0.64	0.88	0.92
V	d(CH₂)₅(Bzl)-D-Phe-Phe-Val-Asn-D-Cys(Bzl)-Pro-Arg(Tos)-Gly-NH₂	83.5	134–6	−9.3		0.60	0.84	0.90
VI	d(CH₂)₅(Bzl)-Tyr(Me)-Ile-Gln-Asn-D-Cys(Bzl)-Pro-Orn(Tos)-Gly-NH₂	85.0	124–6	−25.2	0.67	0.74	0.74	
VII	d(CH₂)₅(Bzl)-Tyr(Me)-Ile-Thr(Bzl)-Asn-D-Cys(Bzl)-Pro-Orn(Tos)-Tyr(Bzl)-NH₂	71.3	198–200	−2.3	0.87	0.84	0.82	
VIII	d(CH₂)₅(Bzl)-Tyr(Me)-Ile-Thr(Bzl)-Asn-D-Cys(Bzl)-Pro-Orn(Tos)-OH	50.2	121–3	−10.0	0.71	0.78	0.72	
IX	d(CH₂)₅(Bzl)-D-Trp-Ile-Thr(Bzl)-Asn-D-Cys(Bzl)-Pro-Orn(Tos)-OH	52.6	136–9	+3.6	0.76	0.74	0.71	
X	d(CH₂)₅(Bzl)-D-Trp-Ile-Gln-Asn-Cys(Bzl)-Pro-Arg(Tos)-Gly-NH₂	80.0	179–82	−12.0		0.47	0.69	0.61
XI	d(CH₂)₅(Bzl)-D-Trp-Ile-Gln-Asn-D-Cys(Bzl)-Pro-Arg(Tos)-Gly-NH₂	70.6	139–43	−15.0		0.62	0.78	0.89

[a] The protected peptides **I–XI** are the immediate protected precursors for the free peptides **1–11** given in Tables 1–5. [b] Yields were calculated on the basis of the amino acid content of the resin. [c] Solvent systems are described in the Experimental Section.

Table 5. Physicochemical Properties of the Free Peptides **1–11**

no.	peptide	yield (%)[a,b]	$[\alpha]^{25}_D$ (deg) (c 0.1, 50% AcOH)	TLC, R_f[c] a	b	d	HPLC[d] t_R (min)	HPLC[e] L⁶	D⁶	formula	MW	$[M+H]^{+}$[f]
1	[D-Cys⁶]AVP	60.6	−99.0		0.06	0.09	25.2	24.6	24.6	C₄₆H₆₅N₁₆O₁₂S₂	1084.2	1085
2	d(CH₂)₅[Tyr(Me)²,D-Cys⁶]AVP	21.3	+10.0		0.19	0.44	39.3	35.3	39.3	C₅₂H₇₄N₁₅O₁₂S₂	1151.4	1153
3	d(CH₂)₅[Tyr(Et)²,D-Cys⁶]VAVP	34.5	+21.0		0.29	0.68	45.3	43.2	45.7	C₅₃H₇₇N₁₄O₁₁S₂	1136.4	1137.5
4	d(CH₂)₅[D-Tyr(Et)²,D-Cys⁶]VAVP	19.0	−75.2		0.15	0.64	46.1	42.1	46.3	C₅₃H₇₇N₁₄O₁₁S₂	1136.4	1137.5
5	d(CH₂)₅[D-Phe²,D-Cys⁶]VAVP	41.6	−84.0		0.20	0.65	43.7	39.7	43.9	C₅₁H₇₃N₁₄O₁₀S₂	1092.3	1094
6	d(CH₂)₅[Tyr(Me)²,D-Cys⁶]OVT	51.7	−7.0	0.17	0.10	0.20	36.6	32.9	37.0	C₄₈H₇₄N₁₂O₁₂S₂	1075.32	1077
7	d(CH₂)₅[Tyr(Me)²,Thr⁴,D-Cys⁶,Tyr-NH₂⁹]OVT	50.6	−23.0	0.31	0.17	0.50	40.0	36.1	40.3	C₅₄H₇₉N₁₁O₁₃S₂	1155.42	1156
8	desGly-NH₂,d(CH₂)₅[Tyr(Me)²,Thr⁴,D-Cys⁶]OVT	55.9	−25.0	0.19	0.12	0.17	39.1	36.6	39.8	C₄₅H₆₉N₉O₁₂S₂	992.23	993.5
9	desGly-NH₂,d(CH₂)₅[D-Trp²,Thr⁴,D-Cys⁶]OVT	19.1	−67.0	0.20	0.13	0.19	43.7	40.1	43.9	C₄₆H₆₇N₁₀O₁₁S₂	1000.3	1002
10	d(CH₂)₅[D-Trp²]AVT	58.8	−118.0	0.11	0.17	0.25	35.2	35.2	39.7	C₅₀H₇₃N₁₅O₁₁S₂	1126.37	1127
11	d(CH₂)₅[D-Trp²,D-Cys⁶]AVT	26.7	−24.0	0.16	0.20	0.30	39.5	35.2	39.7	C₅₀H₇₃N₁₅O₁₁S₂	1126.37	1127

[a] Yields are based on the amount of protected peptide used in the reduction–reoxidation step in each case and are uncorrected for acetic acid and water content. [b] All peptides gave the expected amino acid analysis ratios after hydrolysis ±5%. [c] Solvent systems and conditions are given in the Experimental Section. [d] All peptides were at least 95% pure and, on the basis of this HPLC study and that shown under footnote e, were not contaminated by detectable amounts of the corresponding L-Cys⁶ diastereoisomer. For elution conditions, see the Experimental Section. [e] Retention times were obtained following coinjection of each D-Cys⁶ peptide with its corresponding L-Cys⁶ diastereoisomer. For elution conditions, see the Experimental Section. [f] Data obtained by ES-MS.

pair (peptide **1** and AVP), gave an excellent resolution of the D-Cys⁶/L-Cys⁶ diastereoisomers in each pair as reflected by the clear differences in retention times of the D-Cys⁶ and L-Cys⁶ diastereoisomers in all pairs (Table 5). We can conclude from these HPLC single-injection and coinjection studies that none of the D-Cys⁶-containing AVP and OT antagonists is contaminated by detectable amounts of its L-Cys⁶ diastereoisomer. Electron spray mass spectrometry (ES-MS) spectra, obtained at the University of Michigan Protein and Carbohydrate Structura Facility, were in agreement with the composition of each peptide.

Solid-Phase Synthesis Procedure. Protected peptides were synthesized by manual solid-phase peptide synthesis (SPPS) using a Boc protocol similar to those published before.[32,40–42,47,50–51] Chloromethylated resin (Chemalog or Bachem Inc.; 1% cross-linked S-DVB, 200–400 mesh, 0.7–1.0 mmol/g) was esterified with Boc-Gly, Boc-Orn(Tos), or Boc-Tyr(Bzl) to an incorporation of approximately 0.5 mmol/g by the cesium salt method.[63] Peptidyl resins **VI–XI** were obtained from the corresponding Boc amino acid resins in eight or seven cycles of SPPS. Peptidyl resins **I–V** were obtained by the split synthesis method. Initially, a pentapeptidyl precursor resin was synthesized in four cycles of SPPS and then split, and each sequence was completed in four additional cycles. The protected peptides were cleaved from the resin by ammonolysis in methanol[41,46] (peptides **I–VII**, **X**, and **XI**) or by HBr/TFA treatment[40b,47,48] (peptides **VIII** and **IX**). Protected peptide amides were extracted by hot DMF, precipitated by hot water, and further purified by reprecipitations with DMF/MeOH/Et₂O, until considered pure by TLC. The protected peptides cleaved by HBr were purified by reprecipitations with DMF/MeOH/Et₂O and DMF/water. The protected peptides (**I–XI**; see Table 4) were deblocked with sodium in liquid ammonia.[49] The resulting disulfhydryl compounds were oxidatively cyclized with K₃[Fe(CN)₆] using the normal[52] or a modified reverse procedure.[53] The free cyclic peptides were purified by a two-step gel filtration procedure[54] on Sephadex

G-15 and Sephadex LH-20 columns. The physicochemical properties of the free cyclic peptides (**1–11**) are given in Table 5.

[β-(Benzylthio)-β,β-pentamethylenepropionyl]-D-Tyr-(Et)-Phe-Val-Asn-D-Cys(Bzl)-Pro-Arg(Tos)-Gly-NH₂ (IV; Table 4), Ammonolytic Cleavage. The corresponding C-terminal glycine-containing protected octapeptidyl resin (1.85 g, 0.5 mmol) obtained from eight cycles of solid-phase synthesis as described above was treated with ammonia in the presence of methanol for 72 h in a sealed flask. Following evaporation of the methanolic ammonia, the protected peptide was extracted by hot DMF (32 mL) and precipitated by hot water. The product was collected, dried, and dissolved in DMF (5 mL) and EtOH (20 mL). Ethyl ether was added until the solution became turbid. Solid material was filtered. The solution was evaporated to dryness. The residue was dissolved in hot EtOH, and the product was reprecipitated with ethyl ether (200 mL). Collection and drying in vacuo over P₂O₅ gave the required acyloctapeptide amide **IV** (Table 4). A similar procedure was used for the cleavage and purification of the protected nonapeptide amide **I** and protected acyloctapeptide amides **II**, **III**, **V–VII**, **X**, and **XI** (Table 4).

[β-(Benzylthio)-β,β-pentamethylenepropionyl]-Tyr(Me)-Ile-Thr(Bzl)-Asn-D-Cys(Bzl)-Pro-Orn(Tos)-OH (VIII; Table 4), Acidolytic Cleavage. The corresponding C-terminal tosylornithine-containing protected heptapeptidyl resin (1.43 g, 0.6 mmol) obtained from seven cycles of solid-phase synthesis as described above was suspended in TFA (25 mL) containing anisole (5 mL), and hydrogen bromide was bubbled through the suspension for 45 min. The filtrate was collected, and the resin was resuspended in DCM (12 mL), TFA (12 mL), and anisole (5 mL). HBr bubbling was resumed for a further 40 min. The filtrate was collected, and the resin was washed with DCM/TFA (1:1, v/v, 2 × 20 mL). The filtrates and washings were combined and evaporated on a rotary evaporator. The residue was treated with Et₂O (ca. 250 mL) and placed in the refrigerator for several hours. The resulting

precipitate was collected, washed with ether, and dried in vacuo over P_2O_5. The product was dissolved in DMF (5 mL) and MeOH (15 mL) and precipitated with ether (200 mL). The collected material was dissolved in DMF (10 mL), reprecipitated with water, collected, and dried in vacuo over P_2O_5 to give the desired protected acylheptapeptide **VIII** (Table 4). The same procedure was used for the cleavage and purification of the protected carboxyl-terminating acylheptapeptide **IX** (Table 4).

[1-(β-Mercapto-β,β-pentamethylenepropionic acid),2-O-ethyl-tyrosine,4-valine,6-D-cysteine]arginine-vasopressin (4; Tables 2 and 5). A stirred solution of protected acyloctapeptide amide **IV** (120 mg) in sodium-dried ammonia (ca. 400 mL) was treated at boiling point with a stick of sodium metal contained in a small-bore glass tube until a light-blue color persisted in the solution for ca. 30 s. NH_4Cl was added to discharge the color. The ammonia was evaporated, and the flask was flushed with nitrogen. The residue was dissolved in 50 mL of degassed 50% AcOH and poured into ice-cold water (1000 mL). The pH was adjusted to approximately 7.0 with concentrated ammonium hydroxide. A solution of potassium ferricyanide (0.01 M, 12.0 mL) was added gradually with stirring while the pH was maintained at 7 by the addition of concentrated ammonium hydroxide until a yellow color persisted in the solution. The yellow solution was stirred for an additional 20 min and, after acidification with AcOH to pH 5, then for 10 min with anion-exchange resin (Bio-Rad AG-3, Cl^- form, 10 g damp weight). The suspension was filtered, and the bed was washed with 0.2 N AcOH; the combined filtrate and washings were lyophilized. The resulting powder was desalted on a Sephadex G-15 column (110 × 2.7 cm) eluting with aqueous acetic acid (50%) with a flow rate of 5 mL/h. The eluent was fractionated and monitored for absorbance at 254 nm. The fractions comprising the major peak were checked by TLC, pooled, and lyophilized. The residue was further subjected to gel filtration on a Sephadex G-15 column (100 × 1.5 cm) eluting with aqueous acetic acid (0.2 M) with a flow rate of 4 mL/h. The peptide was eluted in a single peak (absorbance at 254 nm). Lyophilization of pertinent fractions gave the desired peptide **4** (Tables 2 and 5). The same procedure was used to obtain peptides **1-3, 5, 10,** and **11** (Tables 1-3 and 5).

Des-9-glycinamide[1-(β-mercapto-β,β-pentamethylenepropionic acid),2-O-methyltyrosine,4-threonine,6-D-cysteine]ornithine-vasotocin (8; Tables 3 and 5). The protected acylheptapeptide **VIII** (120 mg) was deprotected by sodium in liquid ammonia as above. Reoxidation of the deblocked disulfhydryl peptide was carried out by a modified reverse procedure[53] as follows. The residue was dissolved in 25 mL of 50% AcOH, and the solution was diluted with 75 mL of H_2O. The peptide solution was added dropwise with stirring over a period of 15-30 min to an 800 mL aqueous solution which contained 20 mL of a 0.01 M solution of potassium ferricyanide. Meanwhile, the pH was adjusted to approximately 7.0 with concentrated ammonium hydroxide. The yellow solution was stirred for an additional 20 min. The peptide was isolated and purified as above. However, for the second gel filtration, a Sephadex LH-20 column eluted with 2 M AcOH was used. The same procedure was used for reoxidation of the free cyclic peptides **6, 7,** and **9** (Tables 3 and 5).

References

(1) Manning, M.; Sawyer, W. H. Discovery, development and some uses of vasopressin and oxytocin antagonists. *J. Lab. Clin. Med.* **1989**, *114*, 617-632.

(2) Elands, J.; Barberis, C.; Jard, S.; Tribollet, E.; Dreifuss, J. J.; Bankowski, K.; Manning, M.; Sawyer, W. H. ^{125}I-labeled d(CH_2)$_5$[Tyr(Me)^2,Thr^4,Tyr-NH_2^{9}]OVT: a selective oxytocin receptor ligand. *Eur. J. Pharmacol.* **1987**, *147*, 197-207.

(3) Manning, M.; Bankowski, K.; Barberis, C.; Jard, S.; Elands, J.; Chan, W. Y. Novel approach to the design of synthetic radioiodinated linear V_{1a} receptor antagonists of vasopressin. *Int. J. Pept. Protein Res.* **1992**, *40*, 261-267.

(4) Morel, A.; O'Carroll, A. M.; Brownstein, M. J.; Lolait, S. J. Molecular cloning and expression of a rat V_{1a} vasopressin receptor. *Nature* **1992**, 523-526.

(5) Thibonnier, M.; Auzan, C.; Madhun, Z.; Wilkins, P.; Berti-Mattera, L.; Clauser, E. Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V_{1a} vasopressin receptor. *J. Biol. Chem.* **1994**, *269*, 3304-3310.

(6) Birnbaumer, M.; Seibold, A.; Gilbert, S.; Ishido, M.; Barberis, C.; Antaramian, A.; Brabet, P.; Rosenthal, W. Molecular cloning of the receptor for human antidiuretic hormone. *Nature* **1992**, *357*, 333-335.

(7) Lolait, S. J.; O'Carroll, A. M.; McBride, O. W.; Konig, M.; Morel, A.; Brownstein, M. J. Cloning and characterization of a vasopressin V_2 receptor and possible link to nephrogenic diabetes insipidus. *Nature* **1992**, *357*, 336-339.

(8) Gorbulev, V.; Buchner, H.; Akhundova, A.; Fahrenholtz, F. Molecular cloning and functional characterization of V_2 [8-lysine] vasopressin and oxytocin receptors from a pig kidney cell line. *Eur. J. Biochem.* **1993**, *215*, 1-7.

(9) Sugimoto, T.; Saito, M.; Mochizuki, S.; Watanabe, Y.; Hashimoto, S.; Kawashima, H. Molecular cloning and functional expression of cDNA encoding the human V_{1b} vasopressin receptor. *J. Biol. Chem.* **1994**, *269*, 27088-27092.

(10) (a) Kimura, T.; Tanizawa, O.; Mori, K.; Brownstein, M. J.; Okayama, H. Structure and expression of a human oxytocin receptor. *Nature* **1992**, *356*, 526-529. (b) Chan, W. Y.; Chen, D. L.; Manning, M. Oxytocin receptor subtypes in the pregnant rat myometrium and decidua: Pharmacological differentiations. *Endocrinology* **1993**, *132*, 1381-1386. (c) Chen, D. L.; Chan, W. Y.; Manning, M. Agonist and antagonist specificities of decidual prostaglandin-releasing oxytocin receptors and myometrial uterotonic oxytocin receptors in pregnant rats. *J. Reprod. Fertil.* **1994**, *102*, 337-343.

(11) Michell, R. H.; Kirk, C. J.; Billah, M. M. Hormonal stimulation of phosphatidylinositol breakdown, with particular reference to the hepatic effects of vasopressin. *Biochem. Soc. Trans.* **1979**, *7*, 861-865.

(12) Jard, S.; Barberis, C.; Audigier, S.; Tribollet, E. Neurohypophyseal hormone receptor systems in brain and periphery. *Prog. Brain Res.* **1987**, *72*, 173-187.

(13) Jard, S. Mechanisms of action of vasopressin and vasopressin antagonists. *Kidney Int.* **1988**, *34*, S38-S42.

(14) Liard, J. F. Cardiovascular effects associated with the antidiuretic activity of vasopressin after blockade of its vasoconstrictor action in dehydrated dogs. *Circ. Res.* **1986**, *58*, 631-640.

(15) Lightman, S. L. Molecular insights into diabetes insipidus. *N. Engl. J. Med.* **1993**, *328*, 1562-1563.

(16) (a) Berde, B.; Boissonas, R. A. Basic pharmacological properties of synthetic analogues and homologues of the neurohypophysial hormones. In *Neurohypophysial hormones and similar polypeptides, Handbook of Experimental Pharmacology*; Berde, B., Ed.; Springer: Berlin, 1968; pp 802-870. (b) Manning, M.; Grzonka, Z.; Sawyer, W. H. Synthesis of posterior pituitary hormones and hormone analogues. In *The Pituitary*; Beardwell, C., Robertson, G. L., Eds.; Butterworths: London, 1981; pp 265-296.

(17) Bartter, F. C.; Schwartz, W. B. The syndrome of inappropriate secretion of antidiuretic hormone. *Am. J. Med.* **1967**, *42*, 760-806.

(18) Martinez, M. C.; Aldasoro, M.; Vila, J. M.; Medina, P.; Lluch, S. Responses to vasopressin and desmopressin of human cerebral arteries. *J. Pharmacol. Exp. Ther.* **1994**, *270*, 622-627.

(19) Andersen, L. F.; Lyndrup, J.; Akerlund, M.; Melin, P. Oxytocin receptor blockade: A new principle in the treatment of preterm labor. *Am. J. Perinatol.* **1989**, *6*, 196-199.

(20) Williams, P. D.; Anderson, P. S.; Ball, R. G.; Bock, M. G.; Carroll, L. A.; Chiu, S.-H. L.; Clineschmidt, B. V.; Culberson, J. C.; Erb, J. M.; Evans, B. E.; Fitzpatrick, S. L.; Freidinger, R. M.; Kaufman, M. J.; Lundell, G. F.; Murphy, J. S.; Pawluczyk, J. M.; Perlow, D. S.; Pettibone, D. J.; Pitzenberg, S. M.; Thompson, K. L.; Veber, D. F. 1-(((7,7-Dimethyl-2(S)-2(S)-amino-4-(methylsulfonyl)butyramido)bicyclo[2.2.1]-heptan(S)-yl)methyl)sulfonyl)-4-(2-methylphenyl)piperazine (L-368,899): an orally bioavailable, non-peptide oxytocin antagonist with potential utility for managing preterm labor. *J. Med. Chem.* **1994**, *37*, 565-571.

(21) Ogawa, H.; Yamamura, Y.; Miyamoto, H.; Kondo, K.; Yamasita, H.; Nakaya, K.; Chihara, T.; Mori, T.; Tominaga, M.; Yabuuchi, Y. Orally active, nonpeptide vasopressin V_1 antagonists. A novel series of 1-(1-substituted 4-piperidyl)-3,4-dihydro-2(1H)-quinolinone. *J. Med. Chem.* **1993**, *36*, 2011-2017.

(22) Yamamura, Y.; Ogawa, H.; Yamashita, H.; Chihara, T.; Miamoto, H.; Nakamura, S.; Onogawa, T.; Yamashita, T.; Hosokawa, T.; Mori, T.; Tominaga, M.; Yabuuchi, Y. Characterization of novel aquaretic agent, OPC-3160, as an orally effective, nonpeptide

vasopressin V$_2$ receptor antagonist. *Br. J. Pharmacol.* **1992**, *105*, 787–791.

(23) Serradeil-Le Gal, C.; Wagnon, J.; Garcia, C.; Lacour, C.; Guiraudou, P.; Chrisophe, B.; Villanova, G.; Nisato, D.; Maffrand, J. P.; Le Fur, G.; Guillon, G.; Cantau, B.; Barberis, C.; Trueba, M.; Ala, Y.; Jard, S. Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V$_{1a}$ receptors. *J. Clin. Invest.* **1993**, *92*, 224–231.

(24) Hruby, V. J.; Smith, C. J. Structure-activity relationships of neurohypophysial peptides. In *Chemistry, biology and medicine of neurohypophysial hormones and their analogs*; Udenfriend, S., Meienhofer, J., Eds.; Academic Press: Orlando, FL, 1987; pp 77–207.

(25) Lebl, M. Analogs with inhibitory properties. In *Handbook of neurohypophysial hormone analogs*; Jost, K., Lebl, M., Brtnik, F., Eds.; CRC Press: Boca Raton, FL, 1988; pp 17–74.

(26) Kinter, L. B.; Huffman, W. F.; Stassen, F. L. Antagonists of the antidiuretic activity of vasopressin. *Am. J. Physiol.* **1988**, *254*, F165–F177.

(27) Lāszlo, F. A.; Lāszlo, F., Jr.; DeWied, D. Pharmacology and clinical perspectives of vasopressin antagonists. *Pharmacol. Rev.* **1991**, *43*, 73–108.

(28) Manning, M.; Sawyer, W. H. Design, synthesis and some uses of receptor-specific agonists and antagonists of vasopressin and oxytocin. *J. Recept. Res.* **1993**, *13*, 195–214.

(29) Manning, M.; Sawyer, W. H. Antagonists of the antidiuretic action of arginine vasopressin. U.S. Patent No. 4,491,577, Jan. 1, 1985.

(30) Flouret, G.; Majewski, T.; Brieher, W.; Wilson, L., Jr. Systematic substitution of an oxytocin antagonist with D-amino acids: unexpected high antagonistic potency of the D-Cys⁶-substituted analogue. *J. Med. Chem.* **1993**, *36*, 747–749.

(31) Albrightson-Winslow, C. R.; Brickson, B.; Brooks, D. P.; Bryan, W. M.; Caldwell, N.; Kinter, L. B.; Moore, M. L.; Nambi, P.; Stassen, F. L.; Huffman, W. F. Vasopressin antidiuretic agonist and antagonist activity in dogs: structural and stereochemical relationship between bridge and carboxyl terminus. *J. Pharmacol. Exp. Ther.* **1991**, *256*, 335–340.

(32) (a) Manning, M.; Lammek, B.; Kolodziejczyk, A. M.; Seto, J.; Sawyer, W. H. Synthetic antagonists of *in vivo* antidiuretic and vasopressor responses to arginine-vasopressin. *J. Med. Chem.* **1981**, *24*, 701–706. (b) Manning, M.; Olma, A.; Klis, W. A.; Kolodziejczyk, A. M.; Seto, J.; Sawyer, W. H. Design of more potent antagonists of the antidiuretic response to arginine-vasopressin. *J. Med. Chem.* **1982**, *25*, 45–50.

(33) Manning, M.; Klis, W. A.; Olma, A.; Seto, J.; Sawyer, W. H. Design of more potent and selective antagonists of the antidiuretic responses to arginine-vasopressin devoid of antidiuretic agonism. *J. Med. Chem.* **1982**, *25*, 414–419.

(34) Flouret, G.; Brieher, W.; Mahan, K.; Wilson, L., Jr. Design of potent oxytocin antagonists featuring D-tryptophan at position 2. *J. Med. Chem.* **1991**, *34*, 642–646.

(35) Manning, M.; Kruszynski, M.; Bankowski, K.; Olma, A.; Lammek, B.; Cheng, L. L.; Klis, W. A.; Seto, J.; Haldar, J.; Sawyer, W. H. Solid phase synthesis of 16 potent (selective and nonselective) *in vivo* antagonists of oxytocin. *J. Med. Chem.* **1989**, *32*, 382–391.

(36) Manning, M.; Miteva, K.; Pancheva, S.; Stoev, S.; Wo, N. C.; Chan, W. Y. Design and synthesis of highly selective in vitro and in vivo uterine receptor antagonists of oxytocin: Comparison with Atosiban. *Int. J. Pept. Protein Res.*, in press.

(37) Kruszynski, M.; Lammek, B.; Manning, M.; Seto, J.; Haldar, J.; Sawyer, W. H. [1-(β-mercapto-β,β-cyclopentamethylenepropionic acid), 2-(O-methyl)-tyrosine]arginine vasopressin and [1-(β-mercapto-β,β-cyclopentamethylenepropionic acid)] arginine-vasopressin, two highly potent antagonists of the vasopressor response to arginine-vasopressin. *J. Med. Chem.* **1980**, *23*, 364–368.

(38) Manning, M.; Cheng, L. L.; Balaspiri, L.; Klis, W. A.; Olma, A.; Miteva, K.; Pancheva, S.; Sawyer, W. H.; Wo, N. C.; Chan, W. Y. D-Cys⁶ substitutions in vasopressin and oxytocin antagonist design: A reassessment. *Peptides 1994*; Maia, H. L. S., Schneider, C. H., Eds.; Escom: Leiden.

(39) Manning, M.; du Vigneaud, V. 6-Hemi-D-cysteine-oxytocin, a diastereoisomer of the posterior pituitary hormone oxytocin. *J. Am. Chem. Soc.* **1965**, *87*, 3978–3982.

(40) (a) Merrifield, R. B. Solid phase peptide synthesis. I. The synthesis of a tetrapeptide. *J. Am. Chem. Soc.* **1963**, *85*, 2149–2154. (b) Merrifield, R. B. Solid phase peptide synthesis. III. An improved synthesis of bradykinin. *Biochemistry* **1964**, *9*, 1385–1390.

(41) Stewart, J. M.; Young, J. D. *Solid phase peptide synthesis*; Pierce Chemical Co.: Rockford, IL, 1984.

(42) (a) Manning, M. Synthesis by the Merrifield method of a protected nonapeptide amide with the amino acid sequence of oxytocin. *J. Am. Chem. Soc.* **1968**, *90*, 1348–1349. (b) Manning, M.; Coy, E.; Sawyer, W. H. Solid-phase synthesis of [4-threonine]-oxytocin. A more potent and specific oxytocic agent than oxytocin. *Biochemistry* **1970**, *9*, 3925–3930.

(43) Koening, W.; Geiger, R. New method for the synthesis of peptides: activation of the carboxyl group with dicyclohexylcarbodiimide by using 1-hydroxybenzotriazole as additives. *Chem. Ber.* **1970**, *103*, 788–798.

(44) Bodanszky, M.; du Vigneaud, V. A method of synthesis of long peptide chains using a synthesis of oxytocin as an example. *J. Am. Chem. Soc.* **1959**, *81*, 5688–5691.

(45) Nestor, J. J., Jr.; Ferger, M. F.; du Vigneaud, V. [1-(β-mercapto-β,β-pentamethylenepropionic acid] oxytocin, a potent inhibitor of oxytocin. *J. Med. Chem.* **1975**, *18*, 284–287.

(46) Bodanszky, M.; Sheehan, J. T. Active esters and resins in peptide synthesis. *Chem. Ind.* **1964**, 1423–1424.

(47) Manning, M.; Misicka, A.; Olma, A.; Klis, W. A.; Bankowski, K.; Nawrocka, E.; Kruszynski, M.; Kolodziejczyk, A.; Cheng, L.-L.; Seto, J.; Wo, N. C.; Sawyer, W. H. C-terminal deletions in agonistic and antagonistic analogs of vasopressin that improve their specificities for antidiuretic (V$_2$) and vasopressor (V$_1$) receptors. *J. Med. Chem.* **1987**, *30*, 2245–2252.

(48) Walter, R.; Havran, R. T.; Schwartz, I. L. J. Synthetic metabolites of neurohypophyseal hormones, [des-9-glycinamide] oxytocin and [des-9-glycinamide,des-8-leucine] oxytocin. *J. Med. Chem.* **1976**, *19*, 328–330.

(49) (a) du Vigneaud, V.; Ressler, C.; Swan, J. M.; Roberts, C. W.; Katsoyannis, P. G.; Gordon, S. The synthesis of an octapeptide amide with the hormonal activity of oxytocin. *J. Am. Chem. Soc.* **1953**, *75*, 4879–4880. (b) du Vigneaud, V.; Ressler, C.; Swan, J. M.; Roberts, C. W.; Katsoyannis, P. G. The synthesis of oxytocin. *J. Am. Chem. Soc.* **1954**, *76*, 3115–3121.

(50) Manning, M.; Balaspiri, L.; Acosta, M.; Sawyer, W. H. Solid-phase synthesis of [1-deamino-4-valine]-8-D-arginine-vasopressin (DVDAVP). A highly potent and specific antidiuretic agent possessing protracted effects. *J. Med. Chem.* **1973**, *16*, 975–978.

(51) Manning, M.; Stoev, S.; Kolodziejczyk, A.; Klis, W. A.; Kruszynski, M.; Misicka, A.; Olma, A.; Wo, N. C.; Sawyer, W. H. Design of potent and selective linear antagonists of vasopressor (V$_1$-receptor) responses to vasopressin. *J. Med. Chem.* **1990**, *33*, 3079–3086.

(52) Hope, D. V.; Murti, V. V. S.; du Vigneaud, V. A highly potent analogue of oxytocin, desamino-oxytocin. *J. Biol. Chem.* **1962**, *237*, 1563–1566.

(53) Rivier, J.; Kaiser, R.; Galyean, R. Solid-phase synthesis of somatostatin and glucagon-selective analogs in gram quantities. *Biopolymers* **1978**, *17*, 1927–1938.

(54) Manning, M.; Wuu, T. C.; Baxter, J. W. M. The purification of synthetic oxytocin and analogues by gel filtration on Sephadex G-15. *J. Chromatogr.* **1968**, *38*, 396–398.

(55) Holton, P. A modification of the method of Dale and Laidlaw for standardization of posterior pituitary extract. *Br. J. Pharmacol.* **1948**, *3*, 328–334.

(56) Schild, H. O. pA, a new scale for the measurement of drug antagonism. *Br. J. Pharmacol. Chemother.* **1947**, *2*, 189–206.

(57) Munsick, R. A. Effect of magnesium ion on the response of the rat uterus to neurohypophysial hormone and analogues. *Endocrinology* **1960**, *66*, 451–457.

(58) Chan, W. Y.; Kelly, N. A pharmacologic analysis on the significance of the chemical functional groups of oxytocin to its oxytocic activity and on the effect of magnesium on the *in vitro* and *in vivo* oxytocic activity of neurohypophysial hormones. *J. Pharmacol. Exp. Ther.* **1967**, *156*, 150–158.

(59) Dekanski, J. The quantitative assay of vasopressin. *Br. J. Pharmacol.* **1952**, *7*, 567–572.

(60) Sawyer, W. H. Differences in antidiuretic responses of rats to the intravenous administration of lysine and arginine vasopressins. *Endocrinology* **1958**, *63*, 694–698.

(61) Manning, M.; Kolodziejczyk, A. M.; Klis, W. A.; Olma, A.; Kolodziejczyk, A. B.; Cheng, L. L.; Stoev, S.; Wo, N. C.; Chan, W. Y.; Sawyer, W. H. Approaches to the design of orally active linear vasopressin antagonists. In *Peptides 1992*; Schneider, C. H., Eberle, A. N., Eds.; ESCOM: Leiden, 1993; pp 708–710.

(62) Kolodziejczyk, A. M.; Manning, M. A convenient method for O-alkylation of N-substituted tyrosines using a crown ether. *J. Org. Chem.* **1981**, *46*, 1944–1946.

(63) Gisin, B. F. The preparation of Merrifield-resins through total esterification with cesium salts. *Helv. Chim. Acta* **1973**, *56*, 1476–1482.